Organon Asenapine Study Shows Improved Effect On Negative Schizophrenia Symptoms Over Risperdal
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients treated with asenapine also experienced less weight gain and lower levels of prolactin, a signal associated with improved sexual side effects.
You may also be interested in...
FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.
FDA Accepts NDA For Schering-Plough Antipsychotic Asenapine
Schering’s acquisition of asenapine developer Organon was completed Nov. 19; Dutch firm has previously reported positive data in comparison to J&J’s Risperdal and Lilly’s Zyprexa.
Organon’s Asenapine Shows Less Weight Gain Than Zyprexa In Phase III Trial
Patients taking asenapine had approximately two-fold lower incidence of clinically significant weight gain; efficacy profile was similar to Lilly’s olanzapine.